Clinical Trials Browser

Active not recruiting × Erythema × 90 days × Clear all

NCT02411656 2026-01-23

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Phase 2 Active not recruiting

71 enrolled 11 charts

Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms